Calluna Pharma has appointed Mark Gaffney as its CEO, and Mark Altmeyer as Chair of its Board.
Mark Gaffney
Gaffney has more than 20 years of experience in developing corporate strategies, as well as business development and operations — both in private and public biotech companies.
He will lead the corporate strategy team, with a specific focus on Calluna's lead programme.
Prior to Calluna, Gaffney was CEO of Oxular Limited, a company developing novel drug delivery and formulation technologies to treat retinal disorders, where he remains a strategic advisor and member of the Board.
Prior to Oxular, he was the Chief Business and Operating Officer at Verdere Bio.
Mark has also held corporate development and operational positions at Cyclerion Therapeutics and Ironwood Pharmaceuticals and holds a degree in engineering from the University of Pennsylvania and a Juris Doctor degree from Boston University.
Mark Altmeyer
Altmeyer, the newly appointed Independent Chair of the Calluna Board, brings extensive leadership experience, having served on the boards and as an advisor to several pharma and biotech companies.
He is currently Chair of AM-Pharma and also serves on the boards of Novaremed, Merz Therapeutics, Aculys, and Alector, all focusing on CNS and neurological treatments.
Previously, he was President and CEO of Arvelle Therapeutics, Chief Commercial Officer at Axovant Sciences, and held senior roles at Otsuka America and Bristol-Myers Squibb. Altmeyer holds a BA in Economics from Middlebury College and an MBA from Harvard Business School.
Marco Boorsma, General Partner, Forbion, outgoing Chair and member of the Board of Calluna Pharma, added: “Calluna’s tailored approach to targeting the root causes of many diseases can be successful where other treatment strategies have fallen short. The Company and its pipeline are poised for success, and I feel confident as we hand over the Chairmanship to Mark Altmeyer who brings vast experience for the next phase of this journey."